Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC.

Haematologica. 2019 Dec 26. pii: haematol.2019.235648. doi: 10.3324/haematol.2019.235648. [Epub ahead of print]


B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2019 Oct;103(4):351-361. doi: 10.1111/ejh.13292. Epub 2019 Aug 18.


Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Bjørn ME, Brimnes MK, Gudbrandsdottir S, Andersen CL, Poulsen HE, Henriksen T, Hasselbalch HC, Nielsen CH.

Leuk Lymphoma. 2019 Oct;60(10):2549-2557. doi: 10.1080/10428194.2019.1579323. Epub 2019 Feb 20.


Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC.

Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22.


Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.

Damgaard D, Bjørn ME, Jensen PØ, Nielsen CH.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):1203-1208. doi: 10.1080/14756366.2017.1368505.


Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Bjørn ME, Hasselbalch HC.

Expert Rev Hematol. 2017 May;10(5):393-404. doi: 10.1080/17474086.2017.1284583. Epub 2017 Apr 12. Review.


Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.

Damgaard D, Bjørn ME, Steffensen MA, Pruijn GJ, Nielsen CH.

Arthritis Res Ther. 2016 May 5;18(1):102. doi: 10.1186/s13075-016-1000-7.


Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Bjørn ME, Nielsen CH, Hasselbalch HC.

N Engl J Med. 2015 Dec 24;373(26):2579-80. doi: 10.1056/NEJMc1512663. No abstract available.


MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Hasselbalch HC, Bjørn ME.

Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476. Epub 2015 Oct 28. Review.


The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.

Bjørn ME, Hasselbalch HC.

Mediators Inflamm. 2015;2015:648090. doi: 10.1155/2015/648090. Epub 2015 Oct 11. Review.


The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Bjørn ME, Hasselbalch HC.

Clin Case Rep. 2015 Jun;3(6):499-503. doi: 10.1002/ccr3.281. Epub 2015 May 4.


Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC.

Leuk Res Rep. 2015 May 15;4(1):31. doi: 10.1016/j.lrr.2015.04.003. eCollection 2015.


Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

Bjørn ME, Holmström MO, Hasselbalch HC.

Leuk Lymphoma. 2016;57(1):125-8. doi: 10.3109/10428194.2015.1046867. Epub 2015 Sep 23.


Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Hasselbalch HC, Bjørn ME.

N Engl J Med. 2015 Apr 23;372(17):1670. doi: 10.1056/NEJMc1502524. No abstract available.


Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera.

Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC.

Leuk Res Rep. 2014 Aug 1;3(2):73-5. doi: 10.1016/j.lrr.2014.05.003. eCollection 2014. Erratum in: Leuk Res Rep. 2015;4(1):31.


Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC.

Leuk Res. 2014 Jul;38(7):816-21. doi: 10.1016/j.leukres.2014.04.002. Epub 2014 Apr 14.


Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.

Bjørn ME, Andersen CL, Jensen MK, Hasselbalch HC.

Eur J Haematol. 2014 Sep;93(3):224-8. doi: 10.1111/ejh.12332. Epub 2014 Apr 25.


Supplemental Content

Loading ...
Support Center